Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$135 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.9
Industry P/E
--
EV/EBITDA
-1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.9
Face value
--
Shares outstanding
21,491,396
CFO
$-43.11 Mln
EBITDA
$-51.39 Mln
Net Profit
$-64.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| 20.1 | 0.0 | 20.1 | 26.9 | -30.9 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -27.3 | -8.4 | 60.7 | -73.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
|
6.9 | 135.1 | 0.6 | -33.4 | -3,715.8 | -137.1 | -- | 3.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being... developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California. Address: 4300 El Camino Real, Los Altos, CA, United States, 94022 Read more
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
Headquarters
Los Altos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Unicycive Therapeutics Inc (UNCY) is $6.93 (NASDAQ) as of 02-Apr-2026 18:04 EDT. Unicycive Therapeutics Inc (UNCY) has given a return of -30.9% in the last 3 years.
Since, TTM earnings of Unicycive Therapeutics Inc (UNCY) is negative, P/E ratio is not available.
The P/B ratio of Unicycive Therapeutics Inc (UNCY) is 3.86 times as on 31-Mar-2026, a 2 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.15
|
0.75
|
|
2023
|
-0.06
|
-0.46
|
|
2022
|
-0.06
|
-2.32
|
|
2021
|
-0.19
|
0.12
|
|
2020
|
--
|
--
|
The 52-week high and low of Unicycive Therapeutics Inc (UNCY) are Rs 11.00 and Rs 3.72 as of 04-Apr-2026.
Unicycive Therapeutics Inc (UNCY) has a market capitalisation of $ 135 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Unicycive Therapeutics Inc (UNCY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.19
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.